This would help in lowering the heterogeneity of future systematic reviews and in providing clinical ophthalmologists with more precise and more high-quality evidence about the comparison of intravitreal anti-VEGF injections and LPC in the treatment of TR-ROP. This evidence concerns the gene VEGFA and retinopathy of prematurity.